Evaluation of an intravenous heparin nomogram in a coronary care unit

Canadian Journal of Cardiology

Volumn 12, Issue 9, 1996, Pages 802-808

  Paradiso Hardy, Fran L ^a,b   Cheung, Bobby ^a   Geerts, William H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cardiovascular diseases; Heparin; Intravenous therapy; Nomogram

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CORONARY CARE UNIT; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INFORMATION PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; MALE; NOMOGRAM; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY;

ACUTE DISEASE; ANGINA, UNSTABLE; ATRIAL FIBRILLATION; CANADA; CORONARY CARE UNITS; DATA COLLECTION; FEMALE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MYOCARDIAL ISCHEMIA; ONTARIO; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 0029848977     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hirsh J, Fuster V. Guide to anticoagulant therapy. Circulation 1994;89:1449-68.
2. Fennerty A, Thomas P, Backhouse G, Bentley P, Campbell IA, Routledge PA. Audit of control of heparin treatment. BMJ 1985;290:27-8.
3. Elliott CG, Hiltunen SJ, Suchyta M, et al. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med 1994;154:999-1004.
4. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-7.
5. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram, A randomized controlled trial. Ann Intern Med 1993;119:874-81.
6. Gunnarsson PS, Sawyer WT, Montague D, Williams ML, Dupuis RE, Caiola SM Appropriate use of heparin Empiric versus nomogram-based dosing. Arch Intern Med 1995;155:526-32.
7. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989;320:352-7.
8. Kaplan K, Davison R, Parker M, Mayberry B, Feiereisel P, Salinger M. Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1987;59:241-4.
9. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double-blind European Cooperative Study Group. Br Heart J 1992;67:122-8.
10. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant therapy. Chest 1992;102(Suppl):352S-63S.
11. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13.
12. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-95.
13. Granger C, White HD, Hirsh J, Woodlief L, Chesebro J for the GUSTO Trial Investigators. Relationship of aPTT to outcome after thrombolysis: Results from the GUSTO trial. Circulation 1993;88:1068.
14. Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO) lia Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-7.
15. Antman EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial infarction (TIMI) 9A Trial. Circulation 1994;90:1624-30.
16. Neuhaus KL, Essen RV, Tebbe TJ, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994;90:1638-42.
17. Cipolle R, Seifert R, Neilan B, Zaske DE, Haus E. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981;29:387-93.
18. Cipolle RJ, Rodvold KA Heparin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics. Washington: Applied Therapeutics, 1986:908-42
19. Magnani B, PAIMS (Plasminogen Activator Italian Multicenter Study) Investigators. Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator with intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1989;13:19-26.
20. Shojania AM, Tetreault J, Turnbull G The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol 1988;89:19-13.
21. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-9.
22. Hirsh J. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(Suppl):258-75S.